Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06272214

Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy

The Role of Adjuvant Radiotherapy in the Treatment for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Combined With Immunotherapy: A Multi-center, Phase II Randomized Clinical Study

Sponsor: Zhejiang Cancer Hospital

Conditions Adjuvant Radiotherapy

Interventions Adjuvant radiotherapy Observation

Updated 5 times since 2024 Last updated: Jul 12, 2024 Started: Mar 1, 2024 Primary completion: Mar 1, 2027 Completion: Mar 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adjuvant Radiotherapy and is currently actively recruiting participants. Zhejiang Cancer Hospital leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Mar 2024 — Jun 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zhejiang Cancer Hospital

Data source: Zhejiang Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China